D.P. Kovtun1,2, N.M. Anichkov2, O.G. Polushin1, E.V. Ponomaryeva1, G.N. Khrykov3, A.I. Lyubimov3, E.Yu. Kalinina2
1City Clinical Oncology Center, Saint Petersburg
2North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg
3S.M. Kirov Military Medical Academy, Saint Petersburg
Kovtun D.P. ― pathologist of Pathology Department of City Clinical Oncology Center, postgraduate student of the pathological anatomy Department of North-Western State Medical University named after I.I. Mechnikov
56 Veteranov Ave., Saint Petersburg, Russian Federation, 198255, tel. +7-921-870-17-77, e-mail: email@example.com
Abstract. One of the most controversial aspects of postoperative management of patients with colorectal cancer of II stage remains adjuvant chemotherapy, indications to which have not been determined to date. On the basis of 280 observations of colon cancer of the II stage for 2010-2011. 5-year survival rates and their correlation with a number of morphological characteristics of neoplasms, including so-called tumor budding, were estimated. A statistical analysis of the results of the study suggests that the presence of tumor budding in colorectal cancer of stage II, regardless of the degree of differentiation and depth of infestation, should serve as an indication (of course, taking into account the patient’s somatic status) to adjuvant chemotherapy to prevent regional and systemic relapses of a neoplasm.
Key words: colorectal cancer, tumor budding, 5-year survival, chemotherapy.